• Huza Zhang, William Chambers, Savino Sciascia, and Maria J Cuadrado.
• a Louise Coote Lupus Unit , Guy's and St Thomas' NHS Foundation Trust , London , UK.
• Expert Rev Clin Pharmacol. 2016 Jan 1; 9 (5): 681-94.

AbstractSystemic lupus erythematous (SLE) is a chronic autoimmune disease characterised by multisystem involvement and a relapsing remitting course. SLE is a highly heterogeneous condition, with wide variations in both the presentation and severity of disease and the biological markers identified. The use of biologics in SLE has lagged behind that of other rheumatological conditions such as rheumatoid arthritis, in part due to the diverse clinical manifestations of SLE, making it difficult to design appropriate trials for novel treatments. As such, broad immunosuppressive treatment regimens are still widely used in SLE. Nevertheless, in recent years, elucidation of some aspects of SLE pathogenesis have allowed the development of therapies targeted at molecular mediators of SLE. This review provides an update of biological available therapies and those currently under development.

14 keywords...

hide…